Key result
Platelet-activating factor induces biphasic hypotension via dual arterial and prostaglandin-mediated venous dilation.
Answers are grounded in this paper and cite their sources.
We examined the mechanism(s) of hypotensive action of platelet-activating factor (PAF) in anesthetized dogs. PAF (0.5 micrograms/kg i.v.) caused a biphasic hypotension; the first phase was transient and was accompanied by a decrease in systemic vascular resistance and an increase in cardiac output. Aspirin-DL-lysine, a cyclooxygenase inhibitor, had no effect on this phase. The second phase was characterized by a sustained hypotension caused by a reduction in cardiac output and was accompanied by an increase in systemic and pulmonary vascular resistance. The plasma concentrations of 6-ketoprostaglandin F1 alpha and thromboxane B2 also increased. These changes were markedly attenuated by aspirin. Both atrial pressures decreased during the second phase, thereby indicating that the PAF-induced reduction in cardiac output was related to a hindrance in venous return. The hematocrit increased, and aspirin did not affect this change. The extravasation of plasma probably plays a minor role, whereas venodilation would be the primary mechanism of the second-phase hypotension. S-1452, a prostaglandin H2/thromboxane A2 antagonist, abolished the PAF-induced pulmonary vasoconstriction but did not block the hypotensive action of PAF. OKY-046, a thromboxane A2 synthetase inhibitor, almost completely abolished the PAF-induced pulmonary vasoconstriction and the increase in plasma thromboxane B2 level, whereas it potentiated the hypotension and the increase in the plasma concentrations of prostaglandins; aspirin abolished this potentiation. These results suggest that PAF causes hypotension by two different mechanisms: 1) dilatation of resistance vessels independent of prostaglandins and 2) reduction of venous return due to venodilation, as mediated by prostaglandin(s).
No takes yet. Share an insight, caveat, or question.
Yamanaka et al. (1992) studied Platelet-activating factor-induced hypotension. Platelet-activating factor (with aspirin-DL-lysine, S-1452, or OKY-046) was evaluated on Biphasic hypotension, cardiac output, and systemic/pulmonary vascular resistance. Platelet-activating factor induced biphasic hypotension in dogs via prostaglandin-independent resistance vessel dilation and prostaglandin-mediated venodilation.
Synapse has enriched 10 related papers. Consider them for comparative context: